Trametinib Dimethyl Sulfoxide

二甲基亚砜曲美替尼

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameTrametinib Dimethyl Sulfoxide
Drug Alias Name二甲基亚砜曲莫替尼trametinibum曲美替尼trametinibCE-Trametinib +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsUveal melanomaBrain metastasesPoorly Differentiated Thyroid Gland Carcinoma +[46] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaMelanoma
Original Approved Country/TerritoryUnited States
Original Approved Date2013/05/29
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJapan Tobacco Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlbany Research Institute IncNovartis Pharmaceuticals Uk LtdStanford University +[14] 
Inactive CompaniesGenuv IncUniversity Of California San FranciscoGlaxosmithkline Trading Services Ltd +[9] 
Active IndicationsBrain metastasesPoorly Differentiated Thyroid Gland CarcinomaHormone-Resistant Prostate Neoplasms +[38] 
Inactive IndicationsUveal melanomaArteriovenous MalformationsAmyotrophic Lateral Sclerosis +[8] 

Other Information

ATC CodeL01EE01
Related LinksWikipediaDrugBankKEGG